Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexza Pharmaceuticals, Inc.
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
May 22nd, 2009
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) reported financial results for the quarter ended March 31, 2009, and provided an update on its product candidates. The net loss for the quarter, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $6.9 million compared to a net loss of $18.4 million in the comparable period in 2008. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at March 31, 2009 of $40.7 million. "During the first four months of 2009, we have continued to keep pace with our AZ-004 (Staccato(R) loxapine) NDA timeline," said Thomas B....
Source: Health Business Week (2009-05-22)
|
